FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to cell biology, molecular biology, cancer biology and medicine and represents a pharmaceutical composition for targeting to the cells bearing BLyS receptor, containing an effective amount of fused protein consisting of BLyS polypeptide fused with cytotoxic polypeptide where said cytotoxic polypeptide is located on the N-end of fused protein, and BLyS polypeptide is located on the S-end of fused protein, and a pharmaceutically acceptable carrier.
EFFECT: invention provides treatment and prevention of B-cell proliferative disorder.
11 cl, 13 ex, 4 tbl, 20 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED PROTEINS, CONSTRUCTED TOXINS AND METHODS FOR PRODUCTION THEREOF | 2002 |
|
RU2305684C2 |
| PROAPOPTOSIS PROTEINS-CONTAINING THERAPEUTIC AGENTS | 2002 |
|
RU2319709C2 |
| SPARC-BINDING PEPTIDES AND USING THEM | 2009 |
|
RU2491085C2 |
| COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | 2011 |
|
RU2595389C2 |
| NOVEL MODULATORS AND METHODS FOR USE THEREOF | 2011 |
|
RU2592672C9 |
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| OPTIMISED FUSED PROTEIN TACI-FC | 2008 |
|
RU2433141C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
